Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Immunoinflammatory Regulation of Esketamine in Septic Patients — Stella

Home/Esketamine/Immunoinflammatory Regulation of Esketamine in Septic Patients

View on ClinicalTrials.gov

Recruiting

Back to Esketamine trials

Immunoinflammatory Regulation of Esketamine in Septic Patients

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

China

Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Key details

Phase

Post-approval study

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Enrollment target

~100 participants

Started

July 2021

Primary completion

October 2026

Age range

18 Years – 80 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.